Tech Seeker (TS)

Triangle Pharmaceuticals
Profile last edited on: 6/25/2013

NO Business Identifier is currently available for this company.
TS Type
Former SBIR
Year Founded
Last Involved Year

Key People / Management

Location Information

4 University Place 4611 University Drive
Durham, NC 27707
   919 493 5980

Public Profile

Triangle Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the development of new antiviral drug candidates, with a particular focus on therapies for the human immunodeficiency virus (HIV) and the hepatitis B virus. Triangle's proprietary drug candidates under development for HIV and/or hepatitis B include Coviracil(R) (emtricitabine), amdoxovir (formerly DAPD) and clevudine (formerly L-FMAU). In January 2003, Triangle Pharmaceuticals, Inc. was acquired by Gilead Sciences, Inc. Triangle Pharmaceuticals, Inc. develops new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus. Its portfolio consists of several licensed drug candidates in clinical trials and others that are in a preclinical stage. The company's drug candidates include Coviracil (emtricitabine), a potent nucleoside reverse transcriptase inhibitor in Phase III testing for the treatment of HIV; Amdoxovir, a guanosine nucleoside analogue for the treatment of HIV; and Clevudine, a novel pyrimidine nucleoside analogue for the treatment of chronic Hepatitis B.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Privately Held
Stock Info
Received SBIR $$

SBIR firms in the news

There are no news available.